SKIN - NASDAQ
The Beauty Health Company
$0.63
-9.8%The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
At a Glance
Live SnapshotThe Beauty Health Company Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
The Beauty Health Company Income Statement
SKIN • NASDAQ
| The Beauty Health Company Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
300.8M | 334.3M | 398M | 365.9M | 260.1M | 119.1M | 166.6M | 112.3M | |
GROSS PROFIT | ||||||||
(104.4M) | (152M) | (242.9M) | (117.1M) | (81.5M) | (51.9M) | (60.1M) | (39.3M) | |
196.4M | 182.3M | 155.1M | 248.8M | 178.5M | 67.2M | 106.5M | 73M | |
OPERATING INCOME | ||||||||
(217.1M) | (250.1M) | (286M) | (274.6M) | (218.5M) | (84.4M) | (93.1M) | (62.9M) | |
(211.5M) | (243.8M) | (275.9M) | (266.2M) | (210.3M) | (81M) | (88.4M) | (60.5M) | |
(5.6M) | (6.3M) | (10.1M) | (8.4M) | (8.2M) | (3.4M) | (4.6M) | (2.4M) | |
-20.8M | -67.8M | -130.9M | -25.8M | -39.9M | -17.2M | 13.5M | 10.1M | |
PRE-TAX INCOME | ||||||||
(19.3M) | (10.4M) | (13.6M) | (13.4M) | (11.8M) | (21.3M) | (17.1M) | (10M) | |
-10.4M | 6.2M | 9.5M | -4.2M | -11.7M | -21.3M | -17.1M | -10M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -9K | |
14.9M | 38.2M | 29M | 71.2M | -340.7M | -21.3M | -16.4M | -10.1M | |
-5.9M | -29.6M | -101.9M | 45.3M | -380.6M | -38.5M | -2.9M | 10K | |
NET INCOME | ||||||||
(3.6M) | -452K | -1.8M | (1.1M) | -1.9M | -9.3M | -1.3M | (327K) | |
-9.5M | -29.1M | -100.1M | 44.2M | -378.8M | -29.2M | -1.6M | -317K |
SEC Filings
SKIN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K/A 8-K/A 2026 (Amended) N/A | May 21, 2026 | May 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 08, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 22, 2026 | April 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 06, 2026 | March 03, 2026 | 2026 |
Related Guides
Continue your SKIN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.